Audentes Therapeutics (BOLD) Stock Price Down 1.3%

Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) traded down 1.3% on Thursday . The stock traded as low as $19.62 and last traded at $23.91. 14,740 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 758,339 shares. The stock had previously closed at $24.23.

Several analysts recently weighed in on the stock. BidaskClub upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 18th. HC Wainwright set a $40.00 price target on shares of Audentes Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 25th. Cowen assumed coverage on shares of Audentes Therapeutics in a report on Friday, September 7th. They issued a “sell” rating and a $20.00 price target on the stock. B. Riley assumed coverage on shares of Audentes Therapeutics in a report on Friday, September 7th. They issued a “sell” rating and a $20.00 price target on the stock. Finally, Guggenheim assumed coverage on shares of Audentes Therapeutics in a report on Tuesday, October 9th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $36.00.

The stock has a market cap of $904.48 million, a P/E ratio of -7.06 and a beta of 1.99.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.09). During the same quarter last year, the firm earned ($0.88) earnings per share. As a group, equities analysts predict that Audentes Therapeutics Inc will post -3.39 EPS for the current year.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 12,952 shares of the firm’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total transaction of $518,080.00. Following the completion of the transaction, the chief executive officer now owns 12,952 shares of the company’s stock, valued at $518,080. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $36.88, for a total value of $368,800.00. Following the transaction, the vice president now directly owns 100 shares of the company’s stock, valued at approximately $3,688. The disclosure for this sale can be found here. Insiders have sold 77,039 shares of company stock valued at $2,925,260 in the last three months. Insiders own 6.60% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its position in shares of Audentes Therapeutics by 48.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 67,660 shares of the biotechnology company’s stock worth $2,586,000 after purchasing an additional 22,063 shares during the last quarter. MetLife Investment Advisors LLC raised its position in shares of Audentes Therapeutics by 89.0% in the 2nd quarter. MetLife Investment Advisors LLC now owns 14,989 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 7,059 shares during the last quarter. UBS Group AG raised its position in shares of Audentes Therapeutics by 471.9% in the 1st quarter. UBS Group AG now owns 50,532 shares of the biotechnology company’s stock worth $1,518,000 after purchasing an additional 41,696 shares during the last quarter. BlackRock Inc. raised its position in shares of Audentes Therapeutics by 25.4% in the 2nd quarter. BlackRock Inc. now owns 2,458,171 shares of the biotechnology company’s stock worth $93,925,000 after purchasing an additional 497,767 shares during the last quarter. Finally, Partner Fund Management L.P. purchased a new position in shares of Audentes Therapeutics in the 2nd quarter worth about $16,254,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.com-unik.info/2018/11/10/audentes-therapeutics-bold-stock-price-down-1-3.html.

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Further Reading: Should I invest in “strong buy” stocks?

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit